Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.45 |
| ▸ | CA1 | P00915 | 11/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | ARG1 | P05089 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024523 | 0.74 | CA1 (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL31607593 | 0.72 | CA1 (0.32) | CA2CA1CA7CA13 | |
| SCHEMBL3573472 | 0.72 | EPHX1 (0.45) | CA2CA1CA7CA13 | |
| SCHEMBL3371130 | 0.72 | CA1 (0.32) | CA2CA1CA7CA13 | |
| SCHEMBL2835677 | 0.72 | POLB (0.34) | CA2CA1CA7CA13CA9 | |
| SCHEMBL13225635 | 0.72 | CA2 (0.42) | CA2CA1CA7CA13CA9 | |
| SCHEMBL15465474 | 0.70 | LMNA (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL15226205 | 0.70 | CETP (0.38) | CA2CA1CA7CA13 | |
| SCHEMBL9630741 | 0.70 | PNMT (0.30) | CA2CA1CA7CA13 | |
| Potassium Ion SCHEMBL9633093 | 0.70 | PNMT (0.30) | CA2CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488031-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011046774-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-21 | — | — | WO | claimed |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200283425-A1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Wuxi Biocity Biopharmaceutics Co., Ltd. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | TBXA2R, P2RY11, TPMT | CA2 3961/4885CA1 4518/4885CA7 4406/4885 |
| US-20200283425-A1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | TBXA2R, P2RY11, TPMT | CA2 3961/4885CA1 4518/4885CA7 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.